Our specific aims were to: (i) define the level of each tumor marker with the best sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) for diagnosis of HCC; and (ii) to evaluate the clinical utilities of AAG and DCP in HCC patients with low AFP (≤ 20 ng/mL) and high AFP (> 20 ng/mL), especially in attempt to find the best biomarker for diagnosing HCC patients with low AFP. Here, AFP is linked to neoplasm.